Antibodies: A Stable and Specific way to Target Neurochemical Cells
insights from industryEugenia KuteevaPrinciple ScientistAtlas AntibodiesAn interview with Eugenia Kuteeva conducted at SfN 2018, by Alina Shrourou, BSc.
How can Neuroscience markers be used to advance our understanding of the brain?
Neuroscience markers are monoclonal antibodies, developed for identification of the main anatomical and histochemical cell types in the central nervous system. They can therefore be used as markers of the structural and chemical neuroanatomy. These antibodies can also be employed in multiplexing studies, to look, for example, at the expression of your protein of interest in a particular cell type in the nervous system.
Please outline the Neuroscience Marker Panel provided by Atlas Antibodies and which neural lineage and signalling markers they can target.
Our Neuroscience marker panel antibodies are a part of our catalogue of monoclonal antibodies. They target the main cell types in the nervous system, including neurons, astrocytes and oligodendrocytes. We will soon be adding also some microglial markers, which are currently under development. And already now we provide markers for the main neurotransmitter systems, including GABA, glutamate, acetylcholine, dopamine and serotonin systems.
How do Atlas Antibodies develop and validate these markers?
It is important to mention that we have chosen the targets for development of the Neuroscience markers antibodies, based on scientific knowledge on most relevant proteins for identification of different cell types in the brain.
We have an established protocol for development of our monoclonal antibodies, which starts with a careful selection of the most appropriate antigen for immunization. Following immunization, a number of ELISA positive clones are tested in functional applications in order to select the optimal ones for establishing the hybridomas, from which the purified monoclonal antibodies are finally produced. We test the purified monoclonal antibodies thoroughly in all relevant applications before approving and releasing them as products. In addition, all PrecisA Monoclonals are supported with isotype and, when relevant, epitope data.
We put a great effort into the proper validation of our antibodies by following the directions of the International Working Group for Antibody Validation (IWGAV), which recommends the five pillars of validation – genetic, orthogonal, independent antibody, expression of tagged proteins and immunocapture mass spectrometry. We apply these guidelines when validating our antibodies, which we do in the application specific manner.
Furthermore, the majority of PrecisA Monoclonals within the Neuroscience marker panel are tested and approved for use in both human, mouse and rat tissues, which can be beneficial for e.g. translational studies.
What are the other areas of research you provide the antibodies for?
Alongside our Neuroscience marker panel monoclonals, we also have monoclonal antibodies targeting early development of the nervous system, cortical layers markers, as well as organelle, SOX proteins, stem cells and EMT markers to name a few.
On our website, we provide information about the applications and species, which antibodies have been approved for. For the neuroscience marker panel in particular, we have tested and approved them for immunohistochemistry use in human, mouse, and rat tissues.
What can Atlas Antibodies provide to the neuroscience research community by being at Neuroscience 2018?
We put a great effort into developing the most specific and selective antibodies that meet the researchers needs. We take a great care in ensuring that the antibodies are functioning properly for our customers in all recommended applications.
We are here to meet with and talk to scientists in the neuroscience community. We always look forward to events like SfN to be able to discuss our products with our customers in person and to help them to meet their research challenges by providing technical and scientific advice.
Researchers often come to us to discuss which antibodies can be useful for their studies. For example, whether we have antibodies against their specific targets of interest, or which antibodies can be used for identifying specific cell types, groups of cells or particular structures in the nervous system. They may also have questions on experimental protocols. We are present here with our many years of neuroscience expertise to try to meet up and help scientist with their questions.
About Eugenia Kuteeva
Eugenia Kuteeva is a Principle Scientist working with development and validation of novel monoclonal antibodies (PrecisA Monoclonals) at Atlas Antibodies since 2012. Dr. Kuteeva holds a PhD degree in Neuroscience from the Department of Neuroscience at Karolinska Institute. She has a broad experience in life sciences from both academia and industry. Dr. Kuteeva has received several prestigious grants and has published more than 20 peer reviewed scientific papers, reviews and book chapters.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.
.png)
No hay comentarios:
Publicar un comentario